Abstract
COVID-19 booster vaccinations mitigate transmission and reduce the morbidity and mortality associated with infection. However, the optimal date for booster administration remains uncertain. Geographic variation in infection rates throughout the year make it challenging to intuit the best yearly booster administration date to effectively prevent infection, and also challenging to provide best guidance in how to alter booster administration in response to a breakthrough infection. Therefore, we leverage longitudinal antibody and reinfection probabilities with spatiotemporal projections of COVID-19 incidence to develop a geographically-informed approach to optimizing the timing of booster vaccination. Additionally, we assess the delay in booster vaccination that is warranted following breakthrough infections whenever they occur during the year, enabling an approach that acknowledges and respects diverse immune statuses, thereby addressing a substantial barrier to uptake. Our results provide guidance for individual decision-making and healthcare provider recommendations, as well as optimal public health policies.
Significance Statement COVID-19 booster vaccinations are pivotal in reducing disease transmission. However, optimal schedules that would most successfully mitigate adverse health outcomes have not been rigorously determined. Spatial and temporal surges of infections, including breakthrough infections, challenge the implementation of effective boosting strategies. We leverage antibody data and incidence projections to develop a geographically-informed schedule for yearly booster administration and quantify appropriate delays in booster vaccination post-breakthrough infection, thereby accounting for immune status and enhancing vaccination inclusivity. Our findings offer crucial information for individual decision making, healthcare provider guidance, and policy aimed at optimizing the impact of booster vaccination on public health.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Science Foundation of the United States of America RAPID 2031204 (JPT and AD), NSF Expeditions CCF 1918784 (JPT and APG), and support from the University of North Carolina, Charlotte to AD.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data, Mathematica notebooks, imputed monthly proportions, and code underlying this study are publicly available on Zenodo: DOI:10.5281/zenodo.11209811.
